Yemaachi Biotech, a cancer related research agency have discovered two new variants of the deadly global pandemic, corona virus (Covid’19).
According to the researchers, these new variants are of much concern and Ghana’s Health Service and government needs to give some attention to it. In an official twitter post of the agency, Yemaachi Biotech revealed that the two variants, B.1 and B.1.525 have been in circulation since March 2020 in Ghana. They furthermore revealed that, the B.1 variant is said to have an increase rate of transmission. It was first identified in North African countries Morocco and Algeria.
Dr. Yaw Bediako, a Research Fellow and an immuniologist at the West Africa Centre for Cell Biology of Infectious Patheogens (WACCBIP) at the University of Ghana has said that, the B.1 variant as discovered by the Yemaachi Biotech Agency has shown no signs of having the ability to breach the vaccine-induced immunity.
Dr. Bediako who is also the Founder and CEO of Yemaachi Inc. said, “Currently, there is no evidence that this variant is capable of evading vaccine induced immunity. We must keep vaccinating at a high rate to minimize the likelihood that such a variant will emerge”.
However, according to the researchers, the B.1.525 variant has more prevalence in Ghana particularly the Northern and Western regions of the country. This variant was also first identified in West African country, Nigeria. The agenda further indicates that, the variant has mutations that may give the virus the opportunity to evade the immune system partly.
Dr. Nana Kofi Quakyi also indicated that, upon the development of this new variants, government should pragmatic steps to ensure it addresses the nation to create awareness amongst the general public. According to him, the sequential press briefing are very important especially in this moment.
“With the detection of 2 new variants of concern in Ghana, hope we get a #COVID’19 media briefing soon? Those briefings are a core part of risk communication, and they should be scheduled/frequent. Detection of new variants should be an obivious prompt to hold one” Dr. Quakyi reiterated.
Yemaachi Biotech Agency is known to be one of Africa’s Cancer Research Company. Their aim is to use a cutting edge immunogenomics, bioinformatics and articifical intelligence to accelerate the development of cancer detection and cure strategies, ultimately with the goal of loweiring the economic burden of cancer on the African continent.
We will keep a close eye on this story and update you in our subsequent publications….
TheEEA/Accra City Times.
Content created and supplied by: TheEEA (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More